All In Biotech

Drug Trial Radar · NCT06480240

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-992 in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

117

Planned (sponsor's estimate)

Start

Jun 12, 2024

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
OBI Pharma, IncIndustry
Sponsor type
Industry
First posted
Jun 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-992 (Anti-TROP2 antibody drug conjugate, anti-TROP2 monoclonal antibody-cleavable peptide linker-exatecan) as monotherapy. Part B (Cohort Expansion) is intended to further characterize the safety and preliminary clinical activity profile of the RP2D of OBI-992 in subjects with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • OBI-992Drug

    OBI-992 is an antibody-drug conjugate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of OBI-992: incidence of adverse events, serious adverse events, and laboratory abnormalitiesTime frame: Duration of study, up to 2 years and 2 months
  2. Maximum tolerated dose and recommended Phase 2 dose of OBI-992Time frame: Duration of study, up to 2 years and 2 months
  3. Preliminary clinical activity profile - objective response rate (ORR)Time frame: Duration of study, up to 2 years and 2 months
  4. Preliminary clinical activity profile - clinical benefit rate (CBR)Time frame: Duration of study, up to 2 years and 2 months
  5. Preliminary clinical activity profile - duration of response (DOR)Time frame: Duration of study, up to 2 years and 2 months
  6. Preliminary clinical activity profile - disease control rate (DCR)Time frame: Duration of study, up to 2 years and 2 months
  7. Preliminary clinical activity profile - progression-free survivalTime frame: Duration of study, up to 2 years and 2 months

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • California Clinical Trials Medical Group (CCTMG)

    Glendale, California

  • Scripps Green Hospital

    La Jolla, California

  • Karmanos Cancer Institute

    Detroit, Michigan

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

  • NEXT Virginia

    Fairfax, Virginia

  • Taipei Tzu Chi Hospital

    New Taipei City, Xindian District, Taiwan

  • Taipei Medical University - Shuang Ho Hospital

    New Taipei City, Zhonghe District, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.